

Jeff Venstrom, MD

Senior Vice President

Head of Clinical Development and
Medical Affairs,
Foundation Medicine



Tumor site agnostic drug development

A genomics perspective

Jeffrey M. Venstrom, MD

SVP, Head of Clinical Development & Medical Affairs

Disclosure Information

This presentation is sponsored by Foundation Medicine, Inc. The speaker is an employee of Foundation Medicine.

The information contained in this presentation is made for the purpose of general education regarding cancer genomics and diagnostic testing, personalized cancer care, genomic research, and other general information concerning Foundation Medicine testing. Nothing contained in this presentation is intended to constitute medical advice, instruction for medical diagnosis, or instruction for treatment.

This presentation may include data from clinical studies supported by financial contributions from Foundation Medicine.

Foundation Medicine®, FoundationOne®CDx, FoundationOne®Liquid CDx, and FoundationOne®Heme are registered trademarks of Foundation Medicine, Inc.


Please direct all therapy-related questions to the associated pharmaceutical company. Foundation Medicine can only answer questions about our companion diagnostic tests.

For Intended Use and other technical information, including companion diagnostic indications, please see the FoundationOne®CDx Technical Information, available at www.foundationmedicine.com/f1cdx and the FoundationOne®Liquid CDx Technical Information, available at www.foundationmedicine.com/f1liquidcdx.


FoundationOne®Heme is a laboratory developed test that was developed, and its performance characteristics determined by Foundation Medicine. FoundationOne®Heme is not cleared or approved by the U.S. FDA. For more information on FoundationOne®Heme, please see its Technical Specifications at www.foundationmedicine.com.

Tumor-agnostic drug development: a major 21st century breakthrough for making biology actionable


Genomics






Tumor site-informed Rx



Biomarker-defined decision making



#1: **Know** your biomarker




TMB



Fusions

#2: Trust your platform(s)



Liquid, Tissue, Both?
Analytical Validation?

Adaptable?
Reproducible
Algorithms?

#3: Explore nuance



#4: Collaborate Broadly



Design



Execution

Tumor-agnostic drug development

A clinico-genomics perspective



01

Know your biomarker

02

Trust your platform(s)

03

Explore nuance

04

Collaborate broadly

Thank you



**FOUNDATION
MEDICINE**

Confidential – Do Not Distribute

MKT-0285-01.04/2020

© 2020 Foundation Medicine

